Dechra Pharmaceuticals PLC
F:1PK
Balance Sheet
Balance Sheet Decomposition
Dechra Pharmaceuticals PLC
Dechra Pharmaceuticals PLC
Balance Sheet
Dechra Pharmaceuticals PLC
| Jun-2014 | Jun-2015 | Jun-2016 | Jun-2017 | Jun-2018 | Jun-2019 | Jun-2020 | Jun-2021 | Jun-2022 | Jun-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
27
|
46
|
39
|
61
|
80
|
80
|
227
|
118
|
121
|
74
|
|
| Cash |
27
|
46
|
39
|
61
|
80
|
80
|
227
|
118
|
121
|
74
|
|
| Short-Term Investments |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
29
|
29
|
67
|
65
|
79
|
104
|
97
|
119
|
142
|
170
|
|
| Accounts Receivables |
28
|
28
|
59
|
60
|
76
|
91
|
79
|
88
|
122
|
144
|
|
| Other Receivables |
1
|
1
|
8
|
6
|
3
|
13
|
18
|
31
|
20
|
25
|
|
| Inventory |
30
|
32
|
54
|
57
|
87
|
104
|
121
|
150
|
176
|
217
|
|
| Other Current Assets |
1
|
1
|
1
|
2
|
3
|
4
|
3
|
5
|
6
|
7
|
|
| Total Current Assets |
86
|
109
|
162
|
185
|
248
|
292
|
449
|
392
|
444
|
468
|
|
| PP&E Net |
18
|
17
|
38
|
45
|
45
|
58
|
76
|
87
|
100
|
159
|
|
| PP&E Gross |
18
|
17
|
38
|
45
|
45
|
58
|
76
|
87
|
100
|
159
|
|
| Accumulated Depreciation |
10
|
23
|
30
|
35
|
39
|
42
|
51
|
53
|
62
|
65
|
|
| Intangible Assets |
141
|
117
|
242
|
268
|
481
|
435
|
438
|
480
|
485
|
588
|
|
| Goodwill |
55
|
49
|
113
|
128
|
229
|
246
|
254
|
236
|
245
|
335
|
|
| Long-Term Investments |
0
|
0
|
0
|
11
|
11
|
10
|
17
|
17
|
16
|
15
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
1
|
4
|
1
|
3
|
2
|
2
|
5
|
|
| Other Assets |
55
|
49
|
113
|
128
|
229
|
246
|
254
|
236
|
245
|
335
|
|
| Total Assets |
301
N/A
|
292
-3%
|
556
+90%
|
638
+15%
|
1 017
+59%
|
1 042
+2%
|
1 238
+19%
|
1 214
-2%
|
1 293
+7%
|
1 569
+21%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
13
|
10
|
24
|
21
|
33
|
32
|
35
|
35
|
46
|
43
|
|
| Accrued Liabilities |
6
|
13
|
18
|
21
|
30
|
62
|
61
|
74
|
88
|
99
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
2
|
1
|
1
|
1
|
5
|
3
|
3
|
4
|
|
| Other Current Liabilities |
17
|
21
|
22
|
23
|
27
|
23
|
38
|
43
|
22
|
18
|
|
| Total Current Liabilities |
36
|
44
|
66
|
66
|
92
|
118
|
137
|
156
|
159
|
164
|
|
| Long-Term Debt |
32
|
33
|
154
|
181
|
293
|
310
|
353
|
318
|
326
|
501
|
|
| Deferred Income Tax |
22
|
16
|
49
|
49
|
97
|
75
|
63
|
49
|
36
|
76
|
|
| Minority Interest |
0
|
0
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
7
|
5
|
10
|
39
|
31
|
30
|
47
|
59
|
106
|
73
|
|
| Total Liabilities |
96
N/A
|
98
+2%
|
281
+188%
|
337
+20%
|
512
+52%
|
532
+4%
|
600
+13%
|
581
-3%
|
627
+8%
|
814
+30%
|
|
| Equity | |||||||||||
| Common Stock |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Retained Earnings |
89
|
97
|
96
|
109
|
127
|
209
|
211
|
232
|
248
|
171
|
|
| Additional Paid In Capital |
124
|
125
|
172
|
173
|
359
|
278
|
409
|
412
|
414
|
596
|
|
| Treasury Stock |
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
9
|
28
|
6
|
18
|
18
|
22
|
16
|
12
|
3
|
13
|
|
| Total Equity |
205
N/A
|
194
-5%
|
275
+41%
|
301
+10%
|
505
+68%
|
509
+1%
|
638
+25%
|
633
-1%
|
667
+5%
|
755
+13%
|
|
| Total Liabilities & Equity |
301
N/A
|
292
-3%
|
556
+90%
|
638
+15%
|
1 017
+59%
|
1 042
+2%
|
1 238
+19%
|
1 214
-2%
|
1 293
+7%
|
1 569
+21%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
88
|
88
|
93
|
93
|
102
|
103
|
108
|
108
|
108
|
114
|
|